| 前收市價 | 2.9500 |
| 開市 | 2.9000 |
| 買盤 | 0.0000 |
| 賣出價 | 3.4000 |
| 拍板 | 130.00 |
| 到期日 | 2025-06-20 |
| 今日波幅 | 2.9000 - 2.9500 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 167 |
ZacksSAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.
BenzingaBiogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
On Thursday, Sage Therapeutics Inc. (NASDAQ:SAGE) announced that Biogen Inc (NASDAQ:BIIB) had terminated its rights under the collaboration and license agreement with Sage, which was specific to the SAGE-324 program. The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET. Essential tremor is a neurological disorder that causes
Investor's Business DailyIs Eli Lilly Stock A Buy After Snagging Approval For A New Eczema Drug?
The Food and Drug Administration signed off on a new eczema drug from Eli Lilly. Is Eli Lilly stock a buy right now?
